If you suffer from rheumatoid arthritis (RA), Dr. Salah Ahmed’s research project may be just your cup of (green) tea! Dr. Ahmed’s 2014 Innovative Research Grant project, “Mechanism of Mcl-1 regulation in RA by EGCG”, looked at the effects of an anti-inflammatory molecule found in green tea (epigallocatechin-3-gallate or EGCG) on a protein (Mcl-1) found in RA joints.
The Food and Drug Administration (FDA) recently approved the biologic drug sarilumab (Kevzara) for the treatment of rheumatoid arthritis (RA). Sarilumab blocks a protein called interleukin-6 (IL-6), which plays a key role in many inflammatory diseases, including RA. It’s the second IL-6 inhibitor to receive FDA approval for RA; the other, tocilizumab (Actemra), got the nod in 2010.
Continue reading FDA OKs a New Biologic for RA
Up to half of patients treated with the arthritis drug hydroxychloroquine (Plaquenil) are prescribed more than the recommended maximum amount, according to new research. In separate studies, Canadian and U.S. researchers found that 30 to 50 percent of patients didn’t receive the dose outlined in treatment guidelines; a smaller percentage didn’t get recommended eye exams.
Continue reading Wrong Hydroxychloroquine Dose Is Common, Putting Eyes at Risk
Dr. Jose U. Scher, a current Arthritis Foundation-funded investigator, has been looking at the relationship between bacteria and inflammatory diseases for more than 10 years. Dr. Scher’s current Arthritis Foundation funded project, “Pan-Microbiome in At-Risk Subjects and New-Onset Rheumatoid Arthritis (RA),” looks at the relationship of bacteria (or “microbiome” in the mouth, lungs, and intestines) and the development of RA.
Continue reading Researchers on the Path to a Cure – Spotlight on Dr. Jose Scher
Many of us go to multiple doctors’ appointments throughout the year. Between those appointments, work, family life and other things it can be hard to process and remember the information your doctor tells you. One of our funded researchers, Dr. Delesha Carpenter is looking at how well Rheumatoid Arthritis (RA) patients recall information about newly prescribed DMARDs – disease-modifying antirheumatic drugs. Her 3-year Arthritis Foundation funded research project, called “Understanding how RA patients process conflicting information about DMARDs”, was recently presented at the 2016 ACR Annual Meeting & Conference in November.
Continue reading Researchers on the Path to a Cure – Spotlight on Dr. Delesha Carpenter